Ziconotide: A clinical update and pharmacologic review

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 7, 2013, Pages 957-966

  Pope, Jason E ^a   Deer, Timothy R ^a  

^a Center for Pain Relief Inc   (United States)

Author keywords

Chronic pain; Intrathecal drug delivery systems; Neuropathic pain; Prialt; Ziconotide

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; DIHYDROMORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; OPIATE; SUFENTANIL;

ASTHENIA; ATAXIA; CHRONIC PAIN; COCHRANE LIBRARY; CONFUSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; EMBASE; GAIT DISORDER; HEADACHE; HUMAN; INSOMNIA; MEDICAL LITERATURE; MEDLINE; MEMORY DISORDER; NAUSEA; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; PAIN; PRURITUS; REVIEW; SIDE EFFECT; SOMNOLENCE; VOMITING;

ANALGESICS, NON-NARCOTIC; CALCIUM CHANNEL BLOCKERS; CHRONIC PAIN; CLINICAL TRIALS AS TOPIC; HUMANS; INJECTIONS, SPINAL; OMEGA-CONOTOXINS;

EID: 84876044991     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.784269     Document Type: Review

References (57)

1. Available from: http://www. washingtontimes.com/news/2013/jan/11/ny- mayor-bloomberg-limit-painmedication-hospitals/
2. Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 2009;111:881-91
3. Deer TR, Prager J, Levy R, et al. Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15(5):436-64
4. Medtronic update: increased risk of motor stall and loss of or change in therapy with unapproved drug formulations. 2012. http://www.fda.gov/ MedicalDevices/Safety/ListofRecalls/ucm333231.htm
5. Dewilde S, Verdian L, MacLaine GDH. Cost effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin 2009;25(8):2007-19
6. Available from: http://navigatorprogram. com/
7. Westenbroek RE, Hoslins L, Cattarall WA. Localization of Ca 2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 1998;18(16):6319-30
8. Kerr LM, Filloux F, Olivera BM, et al. Autoradiographic localization of calcium challes with [125I] omega-conotoxin in rat brain. Eur J Pharmacol 1988;146:181-3
9. Schmidtko A, Lotsch J, Freynhagen R, et al. Ziconotide for treatment of severe chronic pain. Lancet 2010;375(9725):1569-77
10. Gohil K, Bell JR, Ramachandran J, et al. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 1994;653(1-2):258-66
11. PRIALT (ziconotide intrathecal infusion). Prescribing information. Azur Pharma, Inc., Philadelphia, PA; 2010
12. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291:63-70
13. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebocontrolled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406
14. Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006;9:75-86
15. Webster LR, Fisher R, Chrpata S, Wallace MS. Long-term intrathecal ziconotide for chronic pain: an open labeled study. J Pain Symptom Manage 2009;37(3):363-72
16. Wallace MS, Rauck R, Fisher R, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008;106(2):628e637
17. Ellis DJ, Dissanayake S, McGuire D, et al. Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation 2008;11(1):40-9
18. Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009;6(2):344-51
19. Available from: http://www. chemicalbook.com/ChemicalProduct Property-EN-CB3190092.htm
20. McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat 2007;3(1):69-85
21. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005;25:1084-94
22. Yaksh TL, De Kater A, Dean R, et al. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in dog. Neuromodulation 2012;15:508-19
23. Bowersox SS, Singh T, Nadasdi L, et al. Cardiovascular effects of omega-conotoxins MVIIA and CVID in conscious rats: mechanisms of action. J Cardiovasc Pharmacol 1992;20:756-64
24. Battal B, Kocaoglu M, Bulanski N, et al. Cerebrospinal Fluid Flow imaging by using phase-contrast MR technique. Br J Radiol 2011;84(1004):758-65
25. Bulat M, Klarica M. Recent insights into the hydrodynamics of the cerebrospinal fluid. Brain Res Rev 2011;65:99-112
26. Henry-Feugeas MC, Idy-Peretti I, Baledent O, et al. Origin of Subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging 2000;18(4):387-95
27. Friese S, Hamhaber U, Erb M, et al. The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol 2004;39:120-30
28. Stockman HW. Effect of anatomic fine structure on the flow of cerebrospinal fluid in the spinal subarachnoid space. J Biochem Eng 2006;128:106-14
29. Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry 1990;27:891-6
30. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006;105:169-78
31. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 2010;112:165-75
32. Flack SH, Anderson CM, Bernards CM. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011;112(2):460-4
33. Hejtmanek MR, Harvey TD, Bernards CM. Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion. Reg Anesth Pain Med 2011;36(1):7-11
34. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003;43:624-36
35. Valentino K, Newcomb R, Gadbois T, et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993;90:7894-7
36. Smith H, Deer T. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 2009;5:521-34
37. Brose WG, Gutlove DP, Luther RR, et al. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997;13:256-9
38. Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000;25:274-8
39. Rauck RL, Wallace MS, Burton AW, et al. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract 2009;9:327-37
40. Ridgeway B, Wallace M, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000;85:287-9
41. Lux EA. Successful treatment of a patient with trigeminal neuropathy using Ziconotide. Anesth Analg 2010;110:1195-7
42. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 2010;26:635-44
43. Wang YX, Gao D, Pettus M, et al. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000;84:271-81
44. Wang YX, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000;6:1-20
45. Deer T, Kim C, Bowman R, et al. Intrathecal Ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician 2009;12:E291-6
46. Alicino I, Giglio M, Manca F, et al. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012;153:245-9
47. Dupoiron D, Bore F, Lefebvre-Kuntz D, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician 2012;15:395-403
48. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures containing 25 mug/mL ziconotide and 10 mg/mL or 20 mg/mL morphine sulfate during simulated intrathecal administration. Int J Pharm Compounding 2008;12:552-7
49. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005;8:257-63
50. Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):12-17
51. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):6-11
52. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):1-5
53. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compounding 2008;12:463-6
54. Burton AW, Deer T, Wallace MS, et al. Considerations and methodology for trialing Ziconotide. Pain Physician 2010;13:23-33
55. Mohammed SI, Eldabe S, Simpson KH, et al. Bolus Intrathecal Injection of Ziconotide (Prialt) to evaluate the Option of Continuous Administration via an Implanted Intrathecal Drug Delivery System: a pilot study. Neuromodulation 2012; Epub ahead of print
56. Maier C, Gockel HH, Gruhn K, et al. Increased risk of suicide under intrathecal ziconotide treatment?-A warning. Pain 2011;152:235-7
57. Veixi IE, Hayek SM, Narouze S, et al. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011;12(10):1481-9